Advertisement

Mouse Models of Acute Promyelocytic Leukemia

  • S. C. Kogan
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 313)

Abstract

Mouse models of acute promyelocytic leukemia have been generated through transgenic, knock-in, retroviral, and xenograft strategies. These models have been used to elucidate mechanisms underlying leukemogenesis. Among the areas investigated are the role of reciprocal fusions; effects of target cells, expression levels, and mouse strains; cooperating events; and restrictive and permissive factors. These models have also been used to gain insight into the effects of the immune system on leukemic cells and the mechanism of response to retinoic acid. Furthermore, preclinical studies utilizing these mice have advanced therapy for myeloid leukemia.

Keywords

Acute Myeloid Leukemia Acute Promyelocytic Leukemia Neutrophil Elastase Histone Deacetylase Inhibitor Arsenic Trioxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, Tamassia MG, Sacchi S (1995) Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 80:98–102PubMedGoogle Scholar
  2. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM (1997) a PMLRAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551–2556PubMedCrossRefGoogle Scholar
  3. Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, Xiong SM, Zhu J, Guo WM, Chen JQ, Xu SF, So E, Chan LC, Waxman S, Zelent A, Chen GQ, Dong S, Liu JX, Chen SJ (1999) Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci U S A 96:6318–6323PubMedCrossRefGoogle Scholar
  4. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C, Castaigne S, Fenaux P (1995) All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85:2643–2653PubMedGoogle Scholar
  5. DiGiuseppe JA, LeBeau P, Augenbraun J, Borowitz MJ (1996) Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. Am J Clin Pathol 106:345–351PubMedGoogle Scholar
  6. Estey EH, Giles FJ, Kantarjian H, O’Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M (1999) Molecular remissions induced by liposomal-encapsulated alltrans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94:2230–2235PubMedGoogle Scholar
  7. Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG (1997) Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein. Proc Natl Acad Sci USA 94:10901–10906PubMedCrossRefGoogle Scholar
  8. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ (1997) Alteredmyeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376–387PubMedGoogle Scholar
  9. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, Janin A, Daniel MT, Gourmel B, Degos L, Dombret H, Lanotte M, De The H (2002) In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196:1373–1380PubMedCrossRefGoogle Scholar
  10. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP (1997) Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94:5302–5307PubMedCrossRefGoogle Scholar
  11. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP (1998) Distinct interactions of PML-RARalpha and PLZF-RA Ralpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126–135PubMedCrossRefGoogle Scholar
  12. He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, Pandolfi PP (2000) Two critical hits for promyelocytic leukemia. Mol Cell 6:1131–1141PubMedCrossRefGoogle Scholar
  13. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321–1330PubMedCrossRefGoogle Scholar
  14. Honma Y, Ishii Y, Sassa T, Asahi K (2003) Treatment of human promyelocytic leukemia in the SCID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells. Leuk Res 27:1019–1025PubMedCrossRefGoogle Scholar
  15. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71–76PubMedCrossRefGoogle Scholar
  16. Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A (1995) Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci U S A 92:7401–7405PubMedCrossRefGoogle Scholar
  17. Kamashev D, Vitoux D, De The H (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199:1163–1174PubMedCrossRefGoogle Scholar
  18. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG (2002) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A 99:8283–8288PubMedCrossRefGoogle Scholar
  19. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 11:1447–1452PubMedCrossRefGoogle Scholar
  20. Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM (2000) Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 95:1541–1550PubMedGoogle Scholar
  21. Kogan SC, Brown DE, Shultz DB, Truong BTH, Lallemand-Breitenbach V, Guillemin MC, Lagasse E, Weissman IL, Bishop JM (2001) BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRAR alpha) to block neutrophil differentiation and initiate acute leukemia. J Exp Med 193:531–543PubMedCrossRefGoogle Scholar
  22. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ueda R, Saito H, Naoe T (2001) In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice. Jpn J Cancer Res 92:529–536PubMedGoogle Scholar
  23. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759PubMedCrossRefGoogle Scholar
  24. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187PubMedCrossRefGoogle Scholar
  25. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043–1052PubMedCrossRefGoogle Scholar
  26. Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de The H (2005) Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat Rev Cancer 5:821–827PubMedCrossRefGoogle Scholar
  27. Lane AA, Ley TJ (2003) Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell 115:305–318PubMedCrossRefGoogle Scholar
  28. Le Beau MM, Bitts S, Davis EM, Kogan SC (2002) Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99:2985–2991PubMedCrossRefGoogle Scholar
  29. Le Beau MM, Davis EM, Patel B, Phan VT, Sohal J, Kogan SC (2003) Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia. Blood 102:1072–1074PubMedCrossRefGoogle Scholar
  30. Lin RJ, Evans RM (2000) Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5:821–830PubMedCrossRefGoogle Scholar
  31. Liu W, Guo M, Xu YB, Dao L, Zhou ZN, Wu YL, Chen Z, Kogan SC, Chen GQ (2006) Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood 107:698–707PubMedCrossRefGoogle Scholar
  32. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanziani E, Gobbi A, Pelicci PG (2002) PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100:2989–2995PubMedCrossRefGoogle Scholar
  33. Molica S, Mannella A, Dattilo A, Levato D, Iuliano F, Peta A, Consarino C, Magro S (1996) Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis. Haematologica 81:302–309PubMedGoogle Scholar
  34. Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudde L, Teisserenc H, Carpentier AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9:1413–1417PubMedCrossRefGoogle Scholar
  35. Pandolfi PP (2001) In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene 20:5726–5735PubMedCrossRefGoogle Scholar
  36. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ (1999) A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci USA 96:15103–15108PubMedCrossRefGoogle Scholar
  37. Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ (2001) Mouse models of acute promyelocytic leukemia. Curr Opin Hematol 8:206–211PubMedCrossRefGoogle Scholar
  38. Pollock JL, Lane AA, Schrimpf K, Ley TJ (2005) Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica 90:1042–1049PubMedGoogle Scholar
  39. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G (1995) Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191–1198PubMedGoogle Scholar
  40. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 97:10173–10178PubMedCrossRefGoogle Scholar
  41. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP (2001) Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 193:521–529PubMedCrossRefGoogle Scholar
  42. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddemann W (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59–66PubMedCrossRefGoogle Scholar
  43. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr (1997) A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 89:4282–4289PubMedGoogle Scholar
  44. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z (2004) All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328–5335PubMedCrossRefGoogle Scholar
  45. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O’Farrell AM, Gilliland DG, Le Beau MM, Kogan SC (2003) A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101:3188–3197PubMedCrossRefGoogle Scholar
  46. Sukhai MA, Wu X, Xuan Y, Zhang T, Reis PP, Dube K, Rego EM, Bhaumik M, Bailey DJ, Wells RA, Kamel-Reid S, Pandolfi PP (2004) Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARalpha. Oncogene 23:665–678PubMedCrossRefGoogle Scholar
  47. Walter MJ, Park JS, Lau SK, Li X, Lane AA, Nagarajan R, Shannon WD, Ley TJ (2004) Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol 24:10882–10893PubMedCrossRefGoogle Scholar
  48. Walter MJ, Park JS, Ries RE, Lau SK, McLellan M, Jaeger S, Wilson RK, Mardis ER, Ley TJ (2005) Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proc Natl Acad Sci U S A 102:12513–12518PubMedCrossRefGoogle Scholar
  49. Westervelt P, Pollock JL, Oldfather KM, Walter MJ, Ma MK, Williams A, DiPersio JF, Ley TJ (2002) Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proc Natl Acad Sci U S A 99:9468–9473PubMedCrossRefGoogle Scholar
  50. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ (2003) High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102:1857–1865PubMedCrossRefGoogle Scholar
  51. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  52. Wuchter C, Karawajew L, Ruppert V, Büchner T, Schoch C, Haferlach T, Ratei R, Dörken B, Ludwig WD (1999) Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia 13:1943–1953PubMedCrossRefGoogle Scholar
  53. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439PubMedCrossRefGoogle Scholar
  54. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kahsima K, Matsuo Y, Naoe T (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605–1609PubMedCrossRefGoogle Scholar
  55. Zhang SY, Zhu J, Chen GQ, Du XX, Lu LJ, Zhang Z, Zhong HJ, Chen HR, Wang ZY, Berger R, Lanotte M, Waxman S, Chen Z, Chen SJ (1996) Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice. Blood 87:3404–3409PubMedGoogle Scholar
  56. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, de The H (2005) A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7:143–153PubMedCrossRefGoogle Scholar
  57. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ (2000) Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 97:13306–13311PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • S. C. Kogan
    • 1
  1. 1.Department of Laboratory Medicine and Comprehensive Cancer CenterUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations